GlassScriptPhysician profile
Noah Lindenberg
NPI 1346311073
$10,931.80
in general payments reported to CMS, 2019-2025
86 companies · $1,406 in 2025
The $1,406 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,122 · 2020: $1,283 · 2021: $1,179 · 2022: $1,618 · 2023: $2,491 · 2024: $1,833 · 2025: $1,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,649 · Education: $79.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,649.36 |
| Education | $79.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $808.92 | 2019-2025 | Tepmetko |
| Novartis Pharmaceuticals Corporation | $654.79 | 2019-2025 | |
| Incyte Corporation | $505.64 | 2019-2025 | Monjuvi, Pemazyre, Jakafi |
| Pfizer INC. | $489.06 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $448.02 | 2019-2023 | |
| Celltrion USA INC. | $442.39 | 2023-2025 | Vegzelma |
| Eisai INC. | $378.00 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $370.16 | 2019-2025 | Lynparza, Imfinzi, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $367.48 | 2020-2025 | Opdualag, Opdivo |
| Merck Sharp & Dohme LLC | $364.65 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Pharmacyclics LLC, An Abbvie Company | $287.19 | 2019-2023 | Imbruvica |
| Seagen INC. | $268.47 | 2019-2023 | Padcev, Tukysa, Adcetris |
| Takeda Pharmaceuticals U.S.A., INC. | $251.41 | 2019-2024 | Ninlaro, Fruzaqla, Alunbrig |
| Amgen INC. | $239.71 | 2019-2023 | Vectibix, Xgeva |
| Janssen Biotech, INC. | $239.67 | 2019-2023 | Darzalex, Tecvayli, Erleada |
Show all 86 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noah Lindenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.